Articles tagged "Liver transplantation"

2017 American Transplant Congress
Cardiovascular Events Are a Substantial and Increasing Cause of Graft Loss in Liver Transplant Recipients.
M. Sell, A. Mardis, I. Lee, B. O'Brien, C. Perez, A. Rogers, C. Mardis, N. Patel, J. Fleming, H. Meadows, N. Pilch, K. Chavin, D. Taber.
Pharmacy, Transplant, MUSC, Charleston, SC
Purpose: The overall 1- and 3- year graft survival rates following liver transplant are 89.1% and 79.9%, respectively. While these numbers have vastly improved, they…
2017 American Transplant Congress
Evaluation of the Enhanced Recovery After Surgery Protocol in Living Liver Donors.
A. Khalil, S. Ganesh, C. Hughes, A. Tevar, J. Hatche, S. Esper, A. Humar.
Abdominal Transplant, UPMC, Pittsburgh, PA; Department of Surgery, Ain Shams University, Cairo, Egypt
Background: Enhanced recovery after surgery protocol has proven its efficacy in many surgery fields in controlling pain and promoting early recovery . The implication of…
2017 American Transplant Congress
Long-Term Outcomes After Liver Transplantation (tx) with Everolimus (EVR) and Mycophenolic Acid (MPA) in a Calcineurin Inhibitor-Free Regimen: The CERTITUDE Trial.
F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
¹AP-HP Hôpital Paul Brousse, Villejuif, France; ²AP-HP Hôpital Henri Mondor, Créteil, France; ³CHRU de Lille, Lille, France; ⁴Hôpital Edouard Herriot, Lyon, France; ⁵AP-HP Hôpital Pitié Salpêtrière, Paris, France; ⁶Novartis Pharma SAS, Rueil-Malmaison, France
Background. Long-term outcomes under EVR with MPA and no calcineurin inhibitor are undocumented after liver tx.Methods. CERTITUDE is a prospective, multicenter, observational study of liver…
2017 American Transplant Congress
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.
T. Sandow,¹ H. Bohorquez,² D. Kirsch,¹ A. Albar,¹ P. Thevenot,³ K. Nunez,³ D. DeVun,¹ J. Gimenez,¹ G. Galliano,⁴ A. Cohen,² G. Loss,² D. Kay,¹ P. Gulotta.¹
¹Radiology, Ochsner Clinic Foundation, New Orleans, LA; ²Transplant Surgery, Ochsner Clinic Foundation, New Orleans, LA; ³Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA; ⁴Pathology, Ochsner Clinic Foundation, New Orleans, LA
Purpose:Immune factors are pivotal against disease progression after transplant in hepatocellular carcinoma (HCC). With chemoembolization (TACE) as a bridge to liver transplant, this study compares…
2017 American Transplant Congress
Neutropenia in Kidney and Liver Transplant Recipients: Risk Factors and Consequences.
T. Mavrakanas,¹ M. Fournier,² S. Clairou,² J. Amiel,² D. Vinh,³ C. Coursol,² D. Thirion,² M. Cantarovich.⁴
¹Medicine, Division of Nephrology, McGill University Health Center, Montreal, QC, Canada; ²Pharmacy, McGill University Health Center, Montreal, QC, Canada; ³Medicine, Division of Infectious Diseases, McGill University Health Center, Montreal, QC, Canada; ⁴Medicine, Division of Nephrology, Multi-Organ Transplant Program, McGill University Health Center, Montreal, QC, Canada
Aim: This study aimed to: 1) Define the risk factors associated with neutropenia within the first year post kidney or liver transplantation; 2) Describe the…
2017 American Transplant Congress
Identifying Independent Risk Factors for Graft Loss After Primary Liver Transplantation: A Propensity Score Matched Analysis.
J. Gwiasda, H. Schrem, A. Kaltenborn.
Core Facility Quality Management Transplantation, Hannover Medical School, Hannover, Germany
This study aims to identify independent risk factors for graft loss after primary liver transplantation beyond the occurrence of hepatic artery thrombosis. Graft loss was…
2017 American Transplant Congress
Recovery from Hypophosphatemia as a Predictor of Post-Operative Morbidity in Live Donor Hepatectomy.
O. Serrano,¹ D. Berglund,¹ V. Goduguchinta,¹ A. Reddy,¹ J. Menk,² D. Vock,³ V. Kirchner,¹ R. Kandaswamy,¹ A. Matas,¹ T. Pruett,¹ S. Chinnakotla.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, Minneapolis, MN; ³Biostatistics, School of Public Health, Minneapolis, MN
OBJECTIVE: Live donor hepatectomy (LDH) is associated with significant post-operative hypophosphatemia (POH), which is associated with liver regeneration. We investigated whether the rate of recovery…
2017 American Transplant Congress
Use of Biodegradable Stents for the Treatment of Anastomotic Biliary Strictures in Pediatric Liver Transplant Patients.
J. Quintero,¹ J. Juamperez,¹ V. Cabello,¹ M. Perez,³ I. Bilbao,² J. Molino,¹ R. Charco.²
¹Pediatric Liver Transplant Unit, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain; ²HPB Surgery and Transplants Department, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain; ³Interventional Radiologist Department, Hospital de La Vall d'Hebron, Barcelona, Catalunya, Spain
Objectives To evaluate feasibility, safety and mid-time outcome of pediatric liver transplant patients treated with a biodegradable biliary stent for anastomotic biliary strictures.Methods Retrospective study…
2017 American Transplant Congress
A Novel Technique to Increase Donor Utilization: Our Experience Using High-Dose Tissue Plasminogen Activator Flush in Donation-After-Cardiac-Death Donors for Liver Transplantation.
J. Graham, K. Lorenzen, S. Bellemare, M. Kinkhabwala, J. Rocca.
Surgery, Montefiore Medical Center, Bronx, NY
The utilization of donation-after-cardiac-death (DCD) livers remains generally low. Strategies to address the perceived liabilities associated with DCD organs could influence their utilization in a…
2017 American Transplant Congress
Is It Safe to Use Older Donor Liver Grafts for Older Recipients?
M. Safwan, K. Collins, K. Takahashi, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai.
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
Aim: The safety of liver transplantation (LT) using older donor grafts into older recipients remains to be elucidated. The aim of this study was to…